EUVIMED · CrossrefZeitschrift
Immuno-Oncology and Technology
ISSN 2590-0188 · Elsevier BV
Neueste Artikel
Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care
Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression
Subtype-specific genetic drivers of immune evasion in breast cancer
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
159P Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
60P Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
61P Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities
Immune checkpoint inhibitors in sarcomas: a systematic review
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
132P A phase I clinical trial of QLS31905 in advanced solid tumors
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
Non-viral chimeric antigen receptor (CAR) T cells going viral
172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors
CD47–SIRPα-targeted therapeutics: status and prospects
High multiplex analysis of the immune microenvironment in bone marrow trephine samples using GeoMX™ digital spatial profiling
Tumour mutational burden: primary versus metastatic tissue creates systematic bias
IOTECH: Present, future and the future of the future
A user's perspective on GeoMxTM digital spatial profiling
Gene editing: Towards the third generation of adoptive T-cell transfer therapies
The emerging role of γδ T cells in cancer immunotherapy
T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation
Sprayable gel for postsurgical immunotherapy
Germline genetic host factors as predictive biomarkers in immuno-oncology
Getting visible with exciting IO tech!
EUVIMED